Help paying · Medicare negotiated price · pharmacy cost · cycle 2027
Tradjenta (linagliptin): where help paying exists, what Medicare negotiated and what pharmacies pay
1 assistance program lists linagliptin, each with its income ceiling and when we read it. Medicare's negotiated price for a 30-day supply is $78.00 on January 1, 2027. ClinicalTrials.gov lists 6 recruiting trials that name linagliptin.
Every package we can price
Per-unit prices (per each unit, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 00597-0140-10 | (name not listed) | n/a | n/a | $2.79 | n/a | no NADAC price |
| 00597-0140-30 | Tradjenta Tablets, 5mg | EA | n/a | $2.79 | $16.80 | - |
| 00597-0140-61 | Tradjenta Tablets, 5mg 100s | EA | n/a | $2.79 | $16.80 | - |
| 00597-0140-90 | Tradjenta Tablets, 5mg | EA | n/a | $2.79 | $16.80 | - |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA201280 | Tradjenta Tablets, 5mg, Tradjenta Tablets, 5mg 100s | December 8, 2037 | December 20, 2026 | December 8, 2037 | patent 12364700 with its pediatric extension; 20 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Tradjenta of $1.13 billion in 2024, across 1,446,832 claims and 274,523 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $1.13 billion | 1,446,832 | 274,523 | $779 |
| 2023 | $1.29 billion | 1,496,546 | 286,808 | $864 |
| 2022 | $1.33 billion | 1,615,560 | 305,131 | $821 |
| 2021 | $1.32 billion | 1,693,113 | 318,685 | $778 |
| 2020 | $1.29 billion | 1,831,827 | 330,487 | $703 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 1 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| KY | 77 | $4,185 | Fee-for-service only |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (1 state and package figure is marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 87 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
Programs in our finder that list linagliptin. Each shows its income ceiling, when we read it and whether we checked it against the program's own document. Eligibility is decided by the program, not by us.
- Boehringer Ingelheim Cares Foundation manufacturer
Income at or below 250% FPL ($39,900 for one person), or 200% ($31,920) for the Respimat inhalers. Since 15 October 2026 no new Medicare Part D or Advantage enrollments for its primary care products, including Jardiance
Ceiling read on the program's own document, November 6, 2026.Status. No new patient enrollments for individuals with Medicare Part D or Medicare Advantage prescription drug coverage for Boehringer Ingelheim primary care products (Combivent Respimat, Glyxambi, Jardiance, Jentadueto, Jentadueto XR, Spiriva Respimat, Stiolto Respimat, Synjardy, Synjardy XR, Tradjenta, Trijardy XR). Part D patients actively enrolled as of 2026-10-15 continue through their current enrollment period and may be eligible in 2027 only after annual re-enrollment. Product removals: Cyltezo 2026-07-15; OFEV 2026-09-11 (active patients continue through the end of their enrollment or 2027-12-31); no new enrollments for Aptivus, Atrovent and Striverdi from 2026-10-15. (read November 6, 2026)
Check where your income sits against each ceiling: open the assistance finder. See what has changed and when we last verified each program on the program status board.
Label changes
The FDA file lists no non-manufacturing label change for these applications since November 11, 2025. The most recent one it lists is dated June 20, 2023 (Efficacy).
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Clinical trials recruiting
ClinicalTrials.gov lists 6 interventional trials that name linagliptin and are recruiting, and 6 more not yet recruiting. By phase: Phase 4: 4, Phase 3: 1, Not applicable: 1. The 6 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT06862739 | Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin CombinationDiabetes Mellitus; Type 2 DM | Phase 4 | Nabiqasim Industries (Pvt) Ltd | April 17, 2026 | Pakistan |
| NCT07442006 | Glycemic Variability of Combination Therapies in T2DMType 2 Diabetes Mellitus (T2DM) | Phase 4 | JW Pharmaceutical | March 2, 2026 | South Korea |
| NCT04670666 | Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes MellitusType 2 Diabetes Mellitus | Phase 3 | EMS | December 8, 2025 | Brazil |
| NCT07019012 | Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.T2DM | Phase 4 | Huazhong University of Science and Technology | June 13, 2025 | China |
| NCT06095492 | Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes MellitusKidney Transplant; Complications; Diabetes Mellitus | Not applicable | Medanta, The Medicity, India | December 5, 2024 | India |
| NCT06449833 | Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLDType2 Diabetes Mellitus; Nonalcoholic Fatty Liver Disease | Phase 4 | Zhujiang Hospital | June 10, 2024 | China |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Tradjenta?
The CMS file publishes $78.00 from January 1, 2027. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
The two CMS files do not give a comparable per-unit price for this drug.
Is there help paying for Tradjenta?
1 assistance program lists it in our finder. Eligibility depends on income, coverage and the program's current rules; each program's own page decides.
When could a generic version of Tradjenta arrive?
For Tradjenta, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA201280, December 8, 2037. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Tradjenta?
ClinicalTrials.gov lists 6 recruiting interventional trials that name linagliptin (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Tradjenta?
CMS's Medicare Part D spending dataset reports gross spending on Tradjenta of $1.13 billion in 2024, across 1,446,832 claims and 274,523 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/tradjenta.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.